Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Section Content Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail
-

Aggrenox (aspirin/extended release dipyridamole) 25 mg/200 mg Capsules

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – September 2012

 

Summary View

5 WARNINGS AND PRECAUTIONS

5.1 Risk of Bleeding
  • AGGRENOX increases the risk of bleeding. Risk factors for bleeding include the use of other drugs that increase the risk of bleeding (e.g., anti-platelet agents, anticoagulants heparin, fibrinolytic therapy, and chronic use of NSAIDs) [see Drug Interactions (7.1)]

7 DRUG INTERACTIONS

7.1 Drug Interaction Study Information Obtained From Literature
  • Co-administration with anti-coagulants, anti-platelets, or NSAIDS can increase risk of bleeding
-
-